# BPC-157 TB-500: The 'Wolverine' Two-Peptide Research Blend > BPC-157 TB-500 is a two-peptide research blend pairing a cytoprotective pentadecapeptide with an actin-binding fragment. Both constituents logged against the published evidence; no combination trial exists. Two distinct molecules, two non-overlapping mechanisms, one claimed-but-unproven join. Every constituent finding is logged to its study; the combination row reads NO-HUMAN-DATA. ## What the BPC-157 TB-500 record actually contains BPC-157 TB-500 is not one chemical entity. It is a research-community pairing of two synthetic peptides sold and discussed together as a tissue-repair "stack." Record 01 is BPC-157 (Body Protection Compound 157), a 15-amino-acid pentadecapeptide, sequence `GEPPPGKPADDAGLV`, molecular weight ~1419.5 Da, derived from a protein found in human gastric juice. Record 02 is TB-500, a synthetic N-acetylated heptapeptide, `Ac-LKKTETQ`, molecular weight ~889.0 Da, corresponding to the actin-binding region (residues 17-23) of the 43-residue protein Thymosin Beta-4. The two are paired on a single premise: complementary mechanisms. BPC-157 supplies a local cytoprotective and pro-angiogenic signal; TB-500 supplies an intracellular actin-sequestration signal that regulates cell migration [4]. That is the entire rationale for the blend. The data behind each constituent is real but overwhelmingly preclinical, and the data behind the *combination* does not exist: no controlled clinical trial of BPC-157 with TB-500 has been published for any indication, and no peer-reviewed study defines a synergy dose, ratio, or endpoint for the two given together [5]. This site reads the blend the way a data console reads two records: each finding tagged to the constituent it belongs to, each datum carrying a verification status — VERIFIED for a citation-confirmed single-compound result, PRECLINICAL for rodent-only or in-vitro work, EXTRAPOLATED for the theoretical synergy claim, and NO-HUMAN-DATA for the blend-level gaps. The [BPC-157 TB-500 benefits in the literature](/research-evidence) are summarized one record at a time, with the join marked honestly. For the [human research evidence](/research-evidence) constituent by constituent, the [research dosing context](/dosage) for each peptide, and short answers in the [frequently asked questions](/faq), follow the links across the console. Nothing here is dispensed, prescribed, or sold. ## BPC-157 and TB-500: the two peptides in the Wolverine blend BPC-157 and TB-500 sit on different sides of the cell. BPC-157 acts mainly extracellularly: it up-regulates VEGFR2, drives the downstream VEGFR2-Akt-eNOS angiogenic pathway, modulates the nitric-oxide system, and sensitizes growth-hormone-receptor signaling in tendon fibroblasts [2]. Its flagship preclinical result is tendon repair — in a fully transected rat Achilles model, `10 microg/kg` improved load-to-failure, collagen organization, and tendon integrity versus untreated controls, and in vitro the same compound reversed 4-hydroxynonenal-induced growth inhibition of tendocytes into stimulation [1]. TB-500 acts on the intracellular cytoskeleton. Its `LKKTETQ` motif binds monomeric G-actin in a 1:1 complex and sequesters it by capping both ends, preventing polymerization — a structure established at 2-angstrom resolution by crystallography of a gelsolin-domain-1-Thymosin-Beta-4 hybrid bound to actin [3]. Regulating that actin pool is what governs cell migration, re-epithelialization, and progenitor mobilization [4]. A caveat travels with the second record. "TB-500" as sold is the 7-mer `Ac-LKKTETQ`, but the overwhelming majority of efficacy data attributed to it were generated with FULL-LENGTH Thymosin Beta-4 (~4963 Da), not the fragment [4]. The blend inherits this gap — it leans on full-length-protein data for one of its two components. See the [combination rationale and synergy claim](/research-evidence) for how the two records are argued to fit together, and why that argument is an extrapolation rather than a finding. ## BPC 157 TB 500: naming, spelling, and the 'Wolverine' stack The blend is searched under several spellings. "BPC-157 TB-500," "BPC 157 TB 500" (unhyphenated), "BPC157 TB500," and "the BPC-157 TB-500 stack" all point to the same two-peptide pairing. The popular name is "Wolverine" — a research-community label borrowed for the rapid-healing connotation, not an approved product name, not a single registered substance, and not a manufacturer's brand. That naming matters because the marketing implies more unity than the chemistry supports. There is no standardized composition. Commercial "Wolverine" vials are commonly labeled with a combined per-vial mass — for example ~10 mg BPC-157 plus ~10 mg TB-500 — but no peer-reviewed combination study validates that ratio, and material distributed through non-regulated channels has unverified identity, purity, and actual BPC-157:TB-500 ratio. The name is a convenience; the two records underneath stay distinct. ## The BPC-157 TB-500 stack: what is verified, thin, and absent Read as a status register, the blend's evidence sorts into three states. VERIFIED, single-compound: BPC-157 accelerated transected-Achilles healing in rats [1] and is pro-angiogenic via VEGFR2 [2]; Thymosin Beta-4 sequesters G-actin [3] and carries a broad regenerative mechanism [4]. THIN, human: BPC-157 has only three small pilot studies, and the only completed human safety/PK data in the "TB-500" lineage are for full-length Thymosin Beta-4 — a Phase 1 study in 40 volunteers [5] and a 2021 first-in-human study in 84 volunteers [6] — not the heptapeptide. ABSENT, combination: zero controlled trials of the two together, and no defined synergy dose, ratio, or endpoint [9]. Recent reviews bound the picture honestly. A 2025 systematic review of BPC-157 in orthopaedic sports medicine included 36 studies (35 preclinical, one human), found "no clinical safety data," rated the evidence level IV-V — the lowest tiers — and made no mention of TB-500 or any combination [7]. A 2026 Sports Medicine review of approved and unapproved musculoskeletal peptides concluded that many unapproved peptides show favorable animal-model repair but that rigorous human safety data are scarce, with potential for serious harm, and that such compounds operate largely outside regulatory oversight [8]. For where that leaves access — including the [Wolverine legal status and 503A compounding](/legal-status) picture and the [FDA and WADA status](/legal-status) of both constituents — see the regulatory record; for the underlying studies, the [full reference list](/references). --- Two peptides logged as two records on one console — BPC-157 and TB-500 each weighed against its own studies and its 503A status, the combination row left reading NO-HUMAN-DATA, with no clinic behind the panel and nothing here dispensed.